Atomo Diagnostics Chairman Reports 40% HIV Franchise Growth and 200% OEM Expansion at 2026 AGM

Anjali Anand

05 November 2026 03:14 PM AEDT

Atomo Diagnostics Chairman Reports 40% HIV Franchise Growth and 200% OEM Expansion at 2026 AGM

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Atomo Diagnostics (ASX:AT1) delivered its Chairman's Address at the company's 2026 Annual General Meeting on 5 November 2026, disclosing more than 40% year-on-year growth across its HIV franchise and OEM partnerships combined, with the OEM franchise alone recording more than 200% year-on-year growth during the period.

Key Points

Atomo's HIV franchise grew 21% in FY26, with the company's HIV self-test remaining the first to receive Australian TGA approval
The OEM franchise posted more than 200% year-on-year growth, with Atomo serving as exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos (ASX:LDX) for its FebriDx® product
Dr Cheri Walker transitioned into the Chief Executive role, with founding CEO John Kelly departing after his tenure
The company advanced its Active Syphilis product and added ALT liver and Gen 4 HIV to its proprietary product pipeline during the year
A capital raising was completed during the year to support working capital and organisational restructuring

HIV Franchise Performance and TGA-Approved Self-Test

According to the Chairman's Address, Atomo's HIV franchise delivered solid growth of 21% in FY26, with the company continuing to drive sales through international markets, pharmacies, and public health applications across Australia and New Zealand. The filing states that Atomo's technology is proven, being the first HIV/AIDS self-test approved by the Australian Therapeutic Goods Administration. The address noted that the HIV franchise and OEM partnerships together posted significant year-on-year growth of more than 40% as the company executes its strategy of delivering user-centred rapid testing solutions.

OEM Partnerships and Pascal Cassette Technology

The Chairman's Address disclosed that the OEM franchise posted more than 200% year-on-year growth. Atomo is described in the filing as the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos (ASX:LDX) for its FebriDx® product. The filing states that FebriDx® has previously secured 510k clearance from the US FDA and received a CLIA waiver from the US FDA. The CLIA waiver trial showed that the Pascal cassette enabled greater than 99% concordance between trained and untrained operators using FebriDx®. Development projects with two OEM providers were also completed during the year for Ferritin and Brain Disease/Stroke indications.

Leadership Transition and Strategic Priorities

The filing disclosed that Atomo transitioned its Chief Executive role to Dr Cheri Walker, with a focus on commercial sales, partnerships and new product pipeline development. Founding CEO John Kelly was acknowledged for his long service to the company. The Chairman's Address outlined strategic priorities including expanding the proprietary test pipeline — referencing active syphilis, ALT liver and HIV Gen 4 products — leveraging the platform for new OEM partnerships, and maintaining operational excellence to build towards profitability. The company also commissioned a second blister machine in Sydney and began development of higher cavitation moulding to improve gross margins, according to the filing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.